Last reviewed · How we verify
Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion
Approved treatments
- Rozlytrek · Roche
Rozlytrek works by blocking the activity of a specific protein called the nerve growth factor receptor.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion patent landscape — cliff calendar, originator estates, attackable patents
- Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion treatment landscape brief
- Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion treatment updates RSS
Frequently asked questions about Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion
What drugs treat Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion?
Tracked treatments include Rozlytrek.
What is the treatment for Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion?
Standard treatment for Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion includes Rozlytrek. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion patent cliff · Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion CI report
- Treatment: Rozlytrek · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing